Safety and efficacy of daratumumab in Chinese patients with relapsed or refractory multiple myeloma: a phase 1, dose-escalation study (MMY1003)

Daratumumab monotherapy demonstrated favorable safety and efficacy in relapsed/refractory multiple myeloma (RRMM) patients in the global phase 1/2 GEN501 and phase 2 SIRIUS studies. MMY1003 evaluated daratumumab monotherapy specifically in Chinese patients with RRMM. This 3-part, open-label, phase 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Jing, Hongmei, Yang, Li, Qi, Junyuan, Qiu, Lugui, Fu, Chengcheng, Li, Junmin, Yang, Min, Qi, Ming, Fan, Ni, Ji, Jia, Lu, Jiajia, Li, Yunan, Jin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646544/
https://www.ncbi.nlm.nih.gov/pubmed/36301338
http://dx.doi.org/10.1007/s00277-022-04951-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646544/
https://www.ncbi.nlm.nih.gov/pubmed/36301338
http://dx.doi.org/10.1007/s00277-022-04951-3

Ejemplares similares